---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-020040"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2025-06-11T23:59:59+00:00"
generated_at: "2026-05-19T14:30:36.604057+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vaxart Phase 1 norovirus vaccine data: 141% (GI.1) and 94% (GII.4) antibody titer increases vs first-gen

## Summary
- Second-gen constructs showed 141% increase in GI.1 and 94% increase in GII.4 NBAA titers vs first-gen at high dose, statistically significant.
- All constructs safe and well-tolerated; no vaccine-related serious adverse events reported.
- Vaxart plans Phase 2b as early as H2 2025, Phase 3 potentially in 2026, pending partnership/funding.
- Company believes data supports potential for first-in-class or best-in-class oral norovirus vaccine.

## SEC filing metadata
- accession: 0001437749-25-020040
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2025-06-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774925020040/0001437749-25-020040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774925020040/vxrt20250611_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-020040
- JSON: https://secwatch.observer/filing/0001437749-25-020040.json
- Plain text: https://secwatch.observer/filing/0001437749-25-020040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.